

# Predicting the future risk of lung cancer

## Development and validation of QCancer2 (10-year risk) lung model and evaluating the performance of nine prediction models

Weiqli Liao (presenting), Carol Coupland, Judith Burchardt, David Baldwin, the DART initiative (WP6), Fergus Gleeson, Julia Hippisley-Cox

### Research background and rationale

- ❖ Lung cancer – the most common cause of cancer death in the UK (21%)
- ❖ Screening helps early detection and reduce mortality.
- ❖ Using risk prediction models can target individuals at high risk.
- ❖ The Liverpool Lung Project (LLP<sub>v2</sub>) model (UK) and the Prostate, Lung, Colorectal and Ovarian (PLCO<sub>m2012</sub>) model (US), currently used in the Targeted Lung Health Check Programme, did not have satisfactory model performance.
- ❖ This study aims to develop and validate a model to predict the future risk of lung cancer and suitable for lung cancer screening in the English primary care population.

### Conclusions

- ❖ Compared with the currently used LLP<sub>v2</sub> and PLCO<sub>m2012</sub> models in the Targeted Lung Health Check Programme, the QCancer2 (10-year risk) lung model has better
  - Discrimination
  - Calibration
  - Net benefit
- ❖ The QCancer2 (10-year risk) lung model may be more suitable for selecting individuals at high risk from the English primary care population for lung cancer screening.

Table 1 – Basic information of the nine models

| Prediction models      | QCancer2 (10-year) lung model | LLP     | LCRAT   | PLCO                | Pittsburgh | Bach     |
|------------------------|-------------------------------|---------|---------|---------------------|------------|----------|
| Model versions         | 2015, 2022                    | v2, v3  |         | 2012, 2014          |            |          |
| Country / population   | England                       | England | US      | US                  | US         | US       |
| Predictive horizon     | 1-10 years                    | 5 years | 5 years | 6 years             | 6 years    | 10 years |
| Age range (years)      | 25-84                         | 40-84   | 55-74   | 55-74               | 50-79      | 45-69    |
| Includes never-smokers | Yes                           | Yes     | No      | Only the 2014 model | No         | No       |

Figure 1 – Examples of calibration plots (validation, 910,870 women ever-smoker aged 55-74 years old)





Figure 2 – Decision curve analysis (910,870 women ever-smoker aged 55-74 years old)



Note: similar results between men and women. This poster only presents the results of women due to limited space.

### Box 1 Predictors for the QCancer 2 (10-year risk) lung model

#### Sociodemographic:

- Age
- Sex
- Ethnicity
- Socioeconomic status (Townsend score)

#### Lifestyle factors:

- Smoking status
- Smoking intensity (cigarette per day)
- Alcohol
- BMI

#### Comorbidities:

- COPD
- Asthma
- History of pneumonia
- Venous thromboembolism
- Asbestos exposure
- Personal history of cancer
- Family history of lung cancer

### Methods

#### Stage 1 – Develop and validate the QCancer2 (10-year risk) lung model

❖ **Model development:** Cox regression was used in the derivation dataset (12.99 million) to develop the QCancer2 (10-year risk) lung model in men and women separately, using data from the QResearch® database.

- Multiple imputation was used to replace missing values (5 imputations).
- Fractional polynomials [2] were used to model non-linear relationships between age/BMI/Townsend scores and the outcome (incident diagnosis of lung cancer).

❖ **Model validation:** three discrimination measures (Harrell's C [3], D statistic [4],  $R_D^2$  [5]) and calibration plots were used to evaluate the model performance in the validation cohort (4.14 million).

#### Stage 2 – Model evaluation

❖ The QCancer2 (10-year risk) lung model was compared with the other seven models (LLP<sub>v2</sub>, LLP<sub>v3</sub>, LCRAT, PLCO<sub>M2012</sub>, PLCO<sub>M2014</sub>, Pittsburgh, and Bach models) to predict incident lung cancer diagnosis in two approaches:  
1) In current and ex-smokers aged 55-74 years (the population of the Targeted Lung Health Check Programme),  
2) The QCancer2 lung model compared with each model using its eligibility criteria for the study sample/population.

❖ Model performance was evaluated by discrimination and calibration plots.

❖ Decision curve analysis [6] was used to evaluate the net benefit.

#### References:

1. O'Dowd et al. Thorax. 2022;77(9):882-890;
2. Royston et al. Int J Epidemiol 1999;28(5):964-74.
3. Newson. Stata Journal 2010;10(3):339-58;
4. Royston et al. Stat Med 2004;23:723-48;
5. Royston. Stata J 2006;6:1-14;
6. Vickers et al. Med Decis Making 2006;26(6):565-74.

Table 2 – Discrimination statistics of prediction models in women in the full model and ever-smokers aged 55-74 years old

|                                    | Harrell's C | D statistic | $R_D^2$ |
|------------------------------------|-------------|-------------|---------|
| <b>QCancer2 full model</b>         |             |             |         |
| 25-84 years old                    | 0.90        | 2.81        | 65.4%   |
| <b>Predictive horizon: 5 year</b>  |             |             |         |
| Ever-smokers 55-74 years           |             |             |         |
| QCancer2                           | 0.73        | 1.93        | 46.9%   |
| LLP <sub>v2</sub>                  | 0.65        | 1.56        | 36.7%   |
| LLP <sub>v3</sub>                  | 0.66        | 1.63        | 38.9%   |
| LCRAT                              | 0.64        | 1.57        | 37.1%   |
| <b>Predictive horizon: 6 year</b>  |             |             |         |
| QCancer2                           | 0.73        | 1.91        | 46.5%   |
| PLCO <sub>M2012</sub>              | 0.53        | 1.28        | 28.1%   |
| PLCO <sub>M2014</sub>              | 0.53        | 0.73        | 11.4%   |
| Pittsburgh                         | 0.64        | 1.58        | 37.3%   |
| <b>Predictive horizon: 10 year</b> |             |             |         |
| QCancer2                           | 0.72        | 1.90        | 46.2%   |
| Bach                               | 0.58        | 1.35        | 30.2%   |